Pemetrexed

Generic Name: Pemetrexed

Brand Names: Alimta, Ciambra, Pemfexy, Pemrydi Rtu, Pemetrexed Fresenius Kabi, Pemetrexed Baxter, Pemetrexed Krka, Pemetrexed medac, Pemetrexed Accord, Pemetrexed Sandoz, Armisarte (previously Pemetrexed Actavis)

Drug Type: Small Molecule

Chemical Formula: C_₂₀H_₂₁N_₅O_₆

CAS Number: 137281-23-3

Unique Ingredient Identifier: 04Q9AIZ7NO

Background: Pemetrexed is a chemotherapy drug that is manufactured and marketed by Eli Lilly and Company under the brand name Alimta. It is indicated for use in combination with cisplatin for the treatment of patients with malignant pleural mesothelioma whose disease is either unresectable or who are otherwise not candidates for curative surgery. Its use in non-small cell lung cancer has also been investigated. Pemetrexed was first approved by the FDA in February 4, 2004.

Indication: Pemetrexed is indicated for the treatment of the following conditions:

Non-squamous non-small cell lung cancer (NSCLC)

Malignant pleural mesothelioma

Associated Conditions: Metastatic Cervical Cancer, Metastatic Non-squamous Non Small Cell Lung Cancer, Metastatic Urothelial Carcinoma (UC), Ovarian Cancer, Locally advanced nonsquamous non-small cell lung cancer, Recurrent, metastatic Non-squamous Non-small-cell Lung Cancer (NSQ NSCLC), Unresectable Malignant Pleural Mesothelioma (MPM), Unresectable Thymoma

Associated Therapies: Monotherapy

Clinical Trials

A Study in Non Small Cell Lung Cancer

Phase 1

Completed

Conditions: Non Small Cell Lung Cancer

Interventions: Drug: Pemetrexed
Drug: Cisplatin
Drug: LY2603618

First Posted Date: 2010-06-09

Last Posted Date: 2018-05-18

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 76

Registration Number: NCT01139775

Locations: 🇪🇸
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Sevilla, Spain

Eribulin Mesylate Administered in Combination With Pemetrexed Versus Pemetrexed Alone as Second Line Therapy in Patients With Stage IIIB or IV Nonsquamous Non Small Cell Lung Cancer

Phase 1

Completed

Conditions: Non Small Cell Lung Cancer

Interventions: Drug: Eribulin mesylate (eribulin; E7389)
Drug: eribulin mesylate
Drug: pemetrexed

First Posted Date: 2010-05-20

Last Posted Date: 2023-06-22

Lead Sponsor: Eisai Inc.

Target Recruit Count: 98

Registration Number: NCT01126736

Pemetrexed and Gemcitabine for Treatment Resistant Patients With Metastatic Colorectal Cancer and KRAS Mutations

Phase 2

Terminated

Conditions: Metastatic Colorectal Cancer

Interventions: Drug: Pemetrexed
Drug: Gemcitabine

First Posted Date: 2010-04-23

Last Posted Date: 2012-04-19

Lead Sponsor: Vejle Hospital

Target Recruit Count: 40

Registration Number: NCT01109615

Locations: 🇩🇰
Vejle Hospital, Vejle, Denmark

Panitumumab Plus Pemetrexed and Cisplatin (PemCisP) Versus PemCis in the First-line Treatment of Patients With Non-small Cell Lung Cancer

Phase 2

Suspended

Conditions: Carcinoma, Non-Small-Cell Lung

Interventions: Drug: Panitumumab
Drug: Pemetrexed
Drug: Cisplatin

First Posted Date: 2010-03-17

Last Posted Date: 2013-03-14

Lead Sponsor: WiSP Wissenschaftlicher Service Pharma GmbH

Target Recruit Count: 134

Registration Number: NCT01088620

Locations: 🇩🇪
LMU-Klinikum der Universität München, Medizinische Klinik München-Innenstadt, München, Germany
🇩🇪
Universitätsklinikum Jena, Klinik für Innere Medizin I, Jena, Germany
🇩🇪
UK-SH, Campus Lübeck, Med. Klinik III, Lübeck, Germany

and more 17 locations

A Study for Participants With Recurrent or Metastatic Squamous Cell Head and Neck Cancer

Phase 2

Completed

Conditions: Head and Neck Neoplasms

Interventions: Drug: Pemetrexed
Drug: Cetuximab
Drug: Carboplatin
Drug: Cisplatin

First Posted Date: 2010-03-16

Last Posted Date: 2014-05-19

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 69

Registration Number: NCT01087970

Locations: 🇺🇸
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Seattle, Washington, United States

Dose Escalation of Bevacizumab With Ambulatory Blood Pressure Monitoring in Patients With Advanced Non-squamous NSCLC

Not Applicable

Completed

Conditions: Advanced Non-squamous Non-Small Cell Lung Cancer

Interventions: Drug: Pemetrexed
Drug: Carboplatin
Drug: Bevacizumab 7.5 mg/kg
Drug: Bevacizumab 15 mg/kg

First Posted Date: 2010-02-05

Last Posted Date: 2019-11-18

Lead Sponsor: University of Chicago

Target Recruit Count: 20

Registration Number: NCT01063283

Locations: 🇺🇸
The University of Chicago Medical Center, Chicago, Illinois, United States
🇺🇸
Ingalls Memorial Hospital, Harvey, Illinois, United States
🇺🇸
North Shore University Health System, Evanston, Illinois, United States

A Study for Patients With Recurrent or Metastatic Squamous Cell Head and Neck Cancer

Phase 2

Completed

Conditions: Head and Neck Neoplasms

Interventions: Drug: Pemetrexed
Drug: Cetuximab
Drug: Cisplatin
Dietary Supplement: Folic Acid
Dietary Supplement: Vitamin B12

First Posted Date: 2010-01-27

Last Posted Date: 2013-09-18

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 66

Registration Number: NCT01057589

Locations: 🇬🇧
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., London, United Kingdom

Carboplatin, Pemetrexed, and Panitumumab in Patients With Advanced Non-Squamous K-ras Wild Type NSCLC

Phase 2

Completed

Conditions: Non-Small-Cell Lung Cancer

Interventions: Drug: Carboplatin
Drug: Pemetrexed
Drug: Panitumumab

First Posted Date: 2010-01-05

Last Posted Date: 2016-05-11

Lead Sponsor: SCRI Development Innovations, LLC

Target Recruit Count: 70

Registration Number: NCT01042288

Locations: 🇺🇸
Northeast Georgia Medical Center, Gainesville, Georgia, United States
🇺🇸
Medical Oncology Associates of Augusta, Augusta, Georgia, United States
🇺🇸
Center for Cancer and Blood Disorders, Bethesda, Maryland, United States

and more 10 locations

A Study in Non-squamous Non Small Cell Lung Cancer in Asian Patients

Phase 4

Completed

Conditions: Non Small Cell Lung Cancer

Interventions: Drug: Pemetrexed
Drug: Carboplatin

First Posted Date: 2009-11-26

Last Posted Date: 2013-08-27

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 109

Registration Number: NCT01020786

Locations: 🇯🇵
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Yamaguchi, Japan

A Study of Alimta/Cisplatin/Gefitinib for Asian Non-smoking Participants With Non Small Cell Lung Cancer

Phase 3

Completed

Conditions: Non Small Cell Lung Cancer

Interventions: Drug: Gefitinib
Drug: Pemetrexed
Drug: Cisplatin

First Posted Date: 2009-11-23

Last Posted Date: 2015-07-08

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 236

Registration Number: NCT01017874

Locations: 🇹🇭
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Hat Yai, Thailand

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy